Literature DB >> 11095202

Adapalene: an update on newer comparative studies between the various retinoids.

L E Millikan1.   

Abstract

BACKGROUND: Extensive modification of the retinoic acid molecular skeleton has resulted in the development of adapalene, a more stable, less irritating compound with receptor selectivity. Adapalene selectively targets nuclear retinoic acid receptors found primarily in the epidermis. Pharmacologic and preclinical studies have demonstrated excellent follicular penetration, comedolytic activity, and anti-inflammatory activity.
METHODS: Recent comparative trials were reviewed.
RESULTS: Adapalene is a useful new agent because of its tolerability and stability. It is a good therapeutic choice for combination with other topical anti-acne medications, such as antimicrobials or benzoyl peroxide. Patient compliance with either combination or single-agent adapalene regimens is likely to be enhanced because of the greater comfort and reduced skin irritation associated with the new compound. Other investigators have confirmed that adapalene gel produces consistent and significantly reduced irritation.
CONCLUSIONS: Recent comparative trials on retinoids have provided new data to aid in the selection of the appropriate combination of topical agents for individual patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11095202     DOI: 10.1046/j.1365-4362.2000.00050.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  10 in total

1.  Adapalene induces adipose browning through the RARβ-p38 MAPK-ATF2 pathway.

Authors:  Na Hyun Lee; Mi Jin Choi; Hana Yu; Jea Il Kim; Hyae Gyeong Cheon
Journal:  Arch Pharm Res       Date:  2022-05-24       Impact factor: 4.946

2.  Electrostatically optimized adapalene-loaded emulsion for the treatment of acne vulgaris.

Authors:  Yun Bae Ji; Hye Yun Lee; Soyeon Lee; Young Hun Kim; Kun Na; Jae Ho Kim; Sangdun Choi; Moon Suk Kim
Journal:  Mater Today Bio       Date:  2022-06-24

3.  Adapalene and Doxorubicin Synergistically Promote Apoptosis of TNBC Cells by Hyperactivation of the ERK1/2 Pathway Through ROS Induction.

Authors:  Umar Mehraj; Irfan Ahmad Mir; Mahboob Ul Hussain; Mustfa Alkhanani; Nissar Ahmad Wani; Manzoor Ahmad Mir
Journal:  Front Oncol       Date:  2022-07-06       Impact factor: 5.738

Review 4.  Current concepts of the pathogenesis of acne: implications for drug treatment.

Authors:  Harald Gollnick
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 5.  Transdermal penetration of topical drugs used in the treatment of acne.

Authors:  Andrea Krautheim; Harald Gollnick
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

6.  Adapalene inhibits the activity of cyclin-dependent kinase 2 in colorectal carcinoma.

Authors:  Xi-Nan Shi; Hongjian Li; Hong Yao; Xu Liu; Ling Li; Kwong-Sak Leung; Hsiang-Fu Kung; Marie Chia-Mi Lin
Journal:  Mol Med Rep       Date:  2015-09-10       Impact factor: 2.952

7.  The efficacy of glycolic acid, salicylic acid, gluconolactone, and licochalcone A combined with 0.1% adapalene vs adapalene monotherapy in mild-to-moderate acne vulgaris: a double-blinded within-person comparative study.

Authors:  Kornphaka Kantikosum; Yuda Chongpison; Natcha Chottawornsak; Pravit Asawanonda
Journal:  Clin Cosmet Investig Dermatol       Date:  2019-02-19

8.  A review of the use of adapalene for the treatment of acne vulgaris.

Authors:  Suleyman Piskin; Erol Uzunali
Journal:  Ther Clin Risk Manag       Date:  2007-08       Impact factor: 2.423

9.  Adapalene Inhibits Prostate Cancer Cell Proliferation In Vitro and In Vivo by Inducing DNA Damage, S-phase Cell Cycle Arrest, and Apoptosis.

Authors:  Hai-Bin Nong; Ya-Nan Zhang; Yi-Guang Bai; Qiong Zhang; Ming-Fu Liu; Quan Zhou; Zhuo-Hua Shi; Gao-Feng Zeng; Shao-Hui Zong
Journal:  Front Pharmacol       Date:  2022-02-22       Impact factor: 5.810

Review 10.  A Clinician's Guide to Topical Retinoids.

Authors:  Melika Motamedi; Ahmad Chehade; Ravina Sanghera; Parbeer Grewal
Journal:  J Cutan Med Surg       Date:  2021-07-22       Impact factor: 2.092

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.